Calidi Biotherapeutics, Inc. Financing Cash Flow
Calidi Biotherapeutics, Inc. (CLDI) reported Financing Cash Flow of $6.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.83M.
- Calidi Biotherapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $5.16M, a 36.37% decline year-over-year.
- Calidi Biotherapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $340.00K, a 97.41% decline year-over-year.
- Calidi Biotherapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $9.48M, a 56.80% increase year-over-year.
- Calidi Biotherapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $17.46M, a 36.20% decline from fiscal 2024.
- Calidi Biotherapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $27.36M, a 5.78% decline from fiscal 2023.
- Calidi Biotherapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $29.04M, a 140.29% increase from fiscal 2022.
- Calidi Biotherapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $12.09M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.99M 10-Q · filed 2026-08-13 | $7.33M derived: sum of 3 quarters · filed 2026-08-13 | $16.81M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $5.16M 10-Q · filed 2026-05-14 | $5.50M derived: sum of 2 quarters · filed 2026-05-14 | $14.98M derived: sum of 3 quarters · filed 2026-05-14 | $14.51M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $9.82M derived: sum of 2 quarters · filed 2026-03-27 | $9.35M derived: sum of 3 quarters · filed 2026-08-13 | $17.46M 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | $9.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $9.01M derived: sum of 2 quarters · filed 2026-08-13 | $17.12M 10-Q · filed 2025-11-13 | $30.23M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$469.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $7.64M 10-Q · filed 2026-08-13 | $20.75M derived: sum of 3 quarters · filed 2026-08-13 | $26.79M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $8.11M 10-Q · filed 2026-05-14 | $21.21M derived: sum of 2 quarters · filed 2026-05-14 | $27.26M derived: sum of 3 quarters · filed 2026-05-14 | $32.46M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $13.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $19.15M derived: sum of 2 quarters · filed 2026-03-27 | $24.35M derived: sum of 3 quarters · filed 2026-03-27 | $27.36M 10-K · filed 2026-03-27 | ||||
| 2024-09-30 | $6.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $11.25M derived: sum of 2 quarters · filed 2025-11-13 | $14.26M 10-Q · filed 2025-11-13 | $11.30M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $5.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $8.21M 10-Q · filed 2025-08-08 | $5.25M derived: sum of 3 quarters · filed 2025-08-08 | $26.89M derived: sum of 4 quarters · filed 2025-08-08 | ||||
| 2024-03-31 | $3.01M 10-Q · filed 2025-05-14 | $55.00K derived: sum of 2 quarters · filed 2025-05-14 | $21.69M derived: sum of 3 quarters · filed 2025-05-14 | $28.27M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | -$2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $18.68M derived: sum of 2 quarters · filed 2025-03-31 | $25.25M derived: sum of 3 quarters · filed 2025-03-31 | $29.04M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $21.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $28.21M derived: sum of 2 quarters · filed 2024-11-12 | $32.00M 10-Q · filed 2024-11-12 | $36.32M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $6.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $10.37M 10-Q · filed 2024-08-13 | $722.50K 10-Q · filed 2023-08-21 | $14.69M derived: sum of 3 quarters · filed 2024-08-13 | $22.45M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $3.79M 10-Q · filed 2024-05-14 | $222.50K 10-Q · filed 2023-05-15 | $8.11M derived: sum of 2 quarters · filed 2024-05-14 | $15.88M derived: sum of 3 quarters · filed 2024-05-14 | $15.88M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $4.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $12.09M derived: sum of 2 quarters · filed 2024-03-15 | $12.09M derived: sum of 3 quarters · filed 2024-03-15 | $12.09M 10-K · filed 2024-03-15 | -$188.75M 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $7.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $7.77M derived: sum of 2 quarters · filed 2023-11-14 | $7.77M 10-Q · filed 2023-11-14 | -$189.55M 10-Q · filed 2022-11-14 | $7.13M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $0.00 10-Q · filed 2023-08-21 | -$640.13K derived: sum of 3 quarters · filed 2023-08-21 | $231.93M derived: sum of 4 quarters · filed 2023-08-21 | ||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | -$640.13K derived: sum of 2 quarters · filed 2023-05-15 | $231.93M derived: sum of 3 quarters · filed 2023-05-15 | $232.15M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | -$640.13K derived: 10-K 9 month − 10-Q 6 month · filed 2023-03-31 | $231.93M derived: sum of 2 quarters · filed 2023-03-31 | $232.15M 10-K · filed 2023-03-31 | |||||
| 2021-09-30 | $232.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-11-14 | $232.79M 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | $213.80K 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |